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The Relationship between Prostate Cancer and Metformin Consumption: 
A Systematic Review and Meta-Analysis study 
Abstract 
Introduction: Prostate cancer is the most common malignant cancer in men worldwide 
and after lung cancer is the second leading cause of cancer deaths in men. The purpose of 
this study was to investigate the relationship between prostate cancer and metformin 
consumption in men. 
Method: The current study is a systematic and meta-analysis review based on the PRISMA 
statement. To access the studies of domestic and foreign databases, Iran Medex, SID, 
Magiran, Iran Doc, Medlib, ProQuest, Science Direct, PubMed, Scopus, Web of Science 
and the Google Scholar search engine were searched during the 2009-2018 period for 
related keywords. In order to evaluate the heterogeneity of the studies, Q test and I
2
 
indicator were used. The data were analyzed using the STATA 15.1 software. 
Results: In 11 studies with a sample size of 877058, the odds ratio of metformin 
consumption for reducing prostate cancer was estimated 0.89 (95% confidence intervalCI: 
0.67-1.17). Meta-regression also showed there was no significant relationship between the 
odds ratio and the publication year of the study. However, there was a significant 
relationship between the odds ratio and the number of research samples. 
Conclusion: Using metformin in men reduces the risk of prostate cancer but it is not 
statistically significant. 
Keywords: metformin, prostate cancer, chronic diseases 
Introduction:  
Chronic diseases have an impact on the economic, social, welfare and quality of life of 
patients and their families (1-6). Prostate cancer is the most common malignant cancer in 
men worldwide and after lung cancer is the second leading cause of cancer deaths in men 
(7-12). On the other hand, apart from skin cancer, prostate cancer is the most common 
cancer among men in the Western world (13). Frequent urination , Urinary inability, 
urinary incontinence , blood in the urine, burning and constant pain in the lower back and 
abdominal pain are also the clinical symptoms of prostate cancer (14). Various factors 
including age, race, genetic factors, environmental factors and family history play an 
important role in the progression of prostate cancer (15, 16). More than 670,000 men with 
prostate cancer are diagnosed annually. Of these, there are about 225,000 in Europe and 
240,000 in the United States (17). The incident rate of prostate cancer varies in different 
races. For instance, it was varied between 4-7 per 100,000 for Asian countries and 70-100 
per 100,000 people for European and North American countries (18, 19). In general, 
Asian men have a lower prostate cancer risk than the western population (20). The 
average length of stay in the hospital for patients with prostate cancer is between 5 to 10 
days, which costs a lot to the individual and the clinical system (21). In spite of the 
extensive global difference in mortality rates among prostate cancer patients of different 
ages, autopsy studies confirmed that in the eighteenth century prostate cancer is present in 
42-80 % of men (22, 23). On the other hand, the incidence and mortality rate of prostate 
cancer in developing countries and less developed countries is increasing (24, 25). The 
annual global incidence of prostate cancer is about 58.9 per 100,000 (26). This figure also 
varies between 3.9 in India and 178.8 in black Americans (24, 27). It is estimated that 
300,000 new cases are annually known of which 41,000 are deadly (28, 29). Metformin 
has a variety of mechanisms that can reduce cancer and carcinogenesis: Direct effect (on 
the tumor and microenvironment) and indirect effects (on the host that may affect the 
tumor). Generally, metformin is directly and indirectly connected via The AKT-Mtor route 
(30-33). The pathway activation mechanisms that are most commonly associated with 
prostate cancer involve: The loss of the repressive PTEN (34), PI3K mutation (35), or 
activation of growth factor receptors such as insulin (36-38). Metformin is the most widely 
used anti-diabetic drug in the world, and only in the United States in 2010, 48 million 
copies were prescribed (39-41). Metformin is a biguanide that is available in most parts of 
the world, it is also inexpensive and has a low side effect and is well tolerated, since it does 
not cause hypoglycemia (42-44). The ability of metformin to reduce hyperinsulinemia may 
also indirectly reduce the risk of prostate cancer (45-47). Elsewhere, laboratory evidence 
has shown that hyperinsulinemia regulates insulin receptors in PCa cells and increases 
the growth of tumor (1, 48). Several invitro and invivo studies have shown that metformin 
acts directly in diminishing the growth specific tumors, decreasing insulin levels in the 
bloodstream or direct activation of AMP kinase (34, 49-51). The purpose of this study was 
to investigate the relationship between metformin use and the risk of prostate cancer in 
men by systematic review and meta-analysis method. 
Methods and materials: 
Study protocol: 
 The present study is a systematic review and meta-analysis study that examines the 
relationship between metformin use and the risk of prostate cancer in men. This 
study was conducted on the basis of the PRISMA
1
 statement (52) which is 
concerned with systematic review and meta-analysis studies. Based on this protocol, 
all stages of the research methodology such as search, selection of studies and 
qualitative assessment of studies and data extraction from the studies were 
conducted by two researchers independently. If there was a difference in the report 
of the researchers, the third researcher investigated and resolved the dispute. 
Search Strategy:  
First, all articles related to the association between metformin use and the risk of 
prostate cancer in men were searched without time limits through domestic 
databases including Iran Medex, SID,  Magiran, Iran Doc, Medlib  and external 
databases such as ProQuest, Science Direct, PubMed, Scopus, Web of Science 
using the keywords "metformin, prostate cancer, systematic review and meta-
analysis" and their various combinations with the operators (AND, OR). In the 
end, in order to complete the search process, related keywords were also searched 
in the Google Scholar search engine. 
Inclusion and Exclusion Criteria:  
Inclusion criteria included: a) epidemiologic studies that included case-control or 
cohort, b) studies that examined the relationship between metformin use and the 
risk of prostate cancer and c) sufficient information for the evaluation such as the 
frequency of variables under investigation. Exclusion criteria also included: a) 
studies that examined the effects of other drugs on prostate cancer, b) studies that 
examined the effect of metformin on diseases other than the prostate cancer, and c) 
lack of reporting sufficient information for the analysis. 
Quality Evaluations study: Researchers assessed the quality of selected articles 
from the methodological aspects such as sampling methods, variables 
measurements, statistical analyses and study objectives using standard STROBE 
checklist (53). The Strobe checklist contains 22 sections that cover different parts of 
a report and the maximum score of a report equals 44, so that a score of 1-15 
indicates poor quality, 16-30 shows average quality and 31-44 is considered to be 
excellent. 
Data Extraction:  
All articles that were of good quality under the Strobe checklist entered the data 
collection stage. To extract the data from the articles, a checklist was already 
prepared by researchers to extract the necessary information such as the name of 
the author, the year of the study, the place where the study took place, the men who 
had consumed metformin and were afflicted to prostate cancer, the men who had 
not taken metformin but had prostate cancer, the men who had taken metformin 
and had no prostate cancer and the men who had not taken metformin and have no 
prostate cancer. 
Statistical Analysis:  
To evaluate the effect of metformin on the risk of prostate cancer in men compared 
to the control group, the odds ratio (OR) index was used. In order to combine the 
results of the studies, OR logarithms were used in each study and the I
2
 index and 
Cochran Q test were used to check the heterogeneity of the studies. In the context 
of the index I2, there are three classifications (less than 25% are Low 
heterogeneity, between 25% and 75% are moderate heterogeneity, and more than 
75% are intense heterogeneity). Considering that the fixed effects model is used for 
the low heterogeneity, and the random effects model are used for the high 
heterogeneity, in this study, a random effects model was used (I
2
=99.6%). Data 
analysis was performed using STATA (Ver. 15.1) software. The significance level 
of the test was considered to be P <0.05. 
Results 
Characteristics of patients: 399 studies were reviewed and evaluated, of which 11 
high-quality studies (with a sample size of 877058 people) entered the meta-analysis 
process. The specifications of the studies assessed and the study selection stages 
based on the PRISMA protocol are shown in Figure 1. 
 Figure1. PRISMA study selection diagram. 
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Table 1: Specifications of studies entered into meta-analysis. 
Reference Author’s 
name 
Duration 
of 
treatment 
type of 
study 
country 
name 
Continent 
name 
Year of 
publicatio
n of the 
article 
age 
average 
OR Lower 
Uppe
r 
Meaningful 
(54) Chen.CB 9 year Cohort Canada America 2017 64 .79  .64  .96  It is 
(55) 
Kabarriti.A 
--- Case-
control 
UK  
Europe 
2015 --- 
.86  .79  .94  It is 
(31) Margel.D 2.9 year Cohort Canada America 2013 76 1.15 1.08 1.23 It is 
(56) 
Randazzo.M 
7.3 year Cohort Switzerla
nd 
Europe 
2015 65/5 
.95  1.09 1.13 It is 
(57) 
Preston.MA 
3.2 year Case-
control 
Denmark 
Europe 
2014 71/7 
.84  .74  .96  It is 
(58) Tesang.C-H <180 day Cohort Taiwan Asia 2014 --- .47  .45  .49  It is 
(59) 
Feng.T 
2 and 4 
year 
Cohort 
USA 
America 
2015 50-75 
1.19 1.01 1.83 It is 
(60) 
Wright.JL 
--- Case-
control 
USA 
America 
2009 --- 
.56  .32  1.00 It is not 
(61) Azoulay.l 10 year cohort Uk Europe 2010 74/1 1.23 .99 1.52 It is not 
(62) Nancy E. 
Morden 
1.3 year Cohort 
Lebanon 
Asia 
2011 77.4 
.97 .76 1.24 It is not 
(63) 
P.D. Home 
4-6 year Case-
control 
UK 
Europe 
2010  
1.22 .86 1.74 It is not 
 
In Probing the relationship between metformin use and the prostate cancer risk in men 
worldwide, the odds ratio of 0.89 (95% confidence intervalCI: 0.67-1.17) was estimated 
which is not statistically significant (Figure 1). 
 
 Diagram 1: Relationship between metformin use and the risk of prostate cancer worldwide 
based on the random effects model. The midpoint of each segment estimates the odds ratio 
and length of the segment, showing the 95% confidence interval in each study. The 
diamond sign shows the odds ratio for all studies. 
 
 
 
 
Table 2: The odds ratio of metformin use and the risk of prostate cancer in different 
subgroups. 
I
2
% P-
Value 
UP-
OR 
LOW-
OR 
OR Number 
of study 
Subgroups  
90.4 0.000 1.21 0.65 0.89 4 America Continent  
74.6 0.003 1.01 0.85 0.93 5 Europe 
97.1 0.000 1.36 0.33 0.67 2 Asia 
94.2 0.000 1.39 0.66 0.96 2 Canada Country  
76.5 0.014 1.40 0.78 1.05 3 UK 
--- --- 0.97 0.93 0.95 1 Switzerland 
--- --- 0.94 0.75 0.84 1 Denmark 
--- --- 0.48 0.46 0.47 1 Taiwan 
87 0.000 1.69 0.39 0.81 2 USA 
--- --- 1.23 0.76 0.97 1 Lebanon 
80.1 0.025 1.05 0.74 0.88 2 64-70 year Age  
87.1 0.000 1.25 0.84 1.03 4 71-77 year 
98.5 0.000 1.16 0.52 0.78 5 Other 
99.2 0.000 1.46 0.58 0.92 6 <5 year follow up 
77.1 0.013 1.12 0.80 0.95 3 5-10 year 
 
 
Chart 2: Meta-regression of the relationship between odds ratio and publication year of 
the study. (P = 0.729) 
  
Chart 3: Meta-regression of the relationship between odds ratio and sample size. (P = 
0.003) 
On the other hand, the odds ratio meta-regression of the metformin use and the risk of 
prostate cancer with the publication year of study is not statistically significant. That is, 
during 2009-2018, the risk of prostate cancer in men was reduced by metformin, but this 
decline is not statistically significant (Figure 2). Meta-regression of the metformin use 
odds ratio and the risk of prostate cancer with sample size of the studies are statistically 
significant. By increasing the sample size, the risk of prostate cancer decreased with 
metformin use and this reflects that more odds ratio was not reported in larger sample 
sizes (Fig. 3). The analysis of publication bias showed that there was no probable 
publication bias in the studies because P = 0.524.That is, most of the published studies in 
this area were covered as a result of the search for studies, and the article search phase 
has been completely done. 
Discussion: 
In the 11 studies we explored, it was concluded that taking metformin would reduce by 
0.89 the risk of prostate cancer in men. As we see in Table 1, in four studies, the odds ratio 
of metformin use to reduce the risk of prostate cancer is not significant, and in the other 7 
studies it is significant, and overall the effect of metformin on reducing the risk of prostate 
cancer is not statistically significant (Table 1). Regarding the conflict in the information 
reported in previous articles, the present article aimed at systematic review and meta-
analyzing the effect of metformin on the reduction of prostate cancer. Meta-regression 
also showed that there is not a significant relationship between the odds ratio of metformin 
use and the risk of prostate cancer in men with the print year of study, but there is a 
significant relationship between the odds ratio of metformin use and the risk of prostate 
cancer and the research sample size. Also, publication bias showed that there was no 
probable publication bias in studies. 
Various meta-analysis studies have already been published in this area. In one study, 
Eleven studies were selected for relevance in terms of intervention, population studied, 
independence, and reporting of cancer incidence or mortality data, reporting 4,042 cancer 
events and 529 cancer deaths. A 31% reduction in overall summary relative risk (0.69; 
95% confidence intervalCI, 0.61-0.79) was found in subjects taking metformin compared 
with other antidiabetic drugs(64). In another meta-analysis, Of 25307 citations identified, 
12 randomized controlled trials (21,595 patients) and 41 observational studies (1,029,389 
patients) met the inclusion criteria. In observational studies there was a significant 
association of exposure to metformin with the risk of cancer death [6 studies, 24,410 
patients, OR:0.65, 95%CI: 0.53-0.80], all malignancies [18 studies, 561,836 patients, 
OR:0.73, 95%CI: 0.61-0.88], liver [8 studies, 312,742 patients, OR:0.34; 95%CI: 0.19-
0.60] colorectal [12 studies, 871,365 patients, OR:0.83, 95%CI: 0.74–0.92], pancreas [9 
studies, 847,248 patients, OR:0.56, 95%CI: 0.36–0.86], stomach [2 studies, 100701 
patients, OR:0.83, 95%CI: 0.76–0.91], and esophagus cancer [2 studies, 100694 patients, 
OR:0.90, 95%CI: 0.83–0.98]. No significant difference of risk was observed in randomized 
trials. Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian 
cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma(65).  
In one research, A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 
randomized controlled trials (RCT)) were identified, involving approximately 7.6 million 
and 137,540 patients with diabetes for observational studies and RCTs, respectively. The 
risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or 
thiazolidinedione’s was associated with a lower risk of cancer incidence (RR = 0.86, 95% 
CI 0.83-0.90, I
2
=88.61%; RR= 0.93, 95% CI 0.91-0.96, I
2
= 0.00% respectively)(66). The 
results of another study showed that metformin decreased lung cancer risk by RR: 0.84 in 
17997 patients with type 2 diabetes. This drug detected to be act an antioxidant for cell 
function(67-73). The results of Moradi-Joo's study showed that metformin reduced the 
risk of breast cancer in 151646 diabetic patients by RR 0.63 (74). In another study, Diana 
Soffer looked at the connection between the use of metformin and the risk of breast cancer 
for 66778 patients and HR: 0.85 (75). As we see in the studies above, taking metformin in 
patients reduces the risk of most cancers. 
Recently, epidemiological studies have shown that the risk of colorectal, liver and 
pancreatic cancer decreases in patients taking metformin (63, 76-80). The results of the 
Zhi Jiang Zhang study on 108,661 people in the 1966-2011 period showed that metformin 
reduced the risk of colorectal cancer in patients with type 2 diabetes by RR: 0.63 (81). In 
meta-analysis, metformin was associated with an estimated 62% reduction in the risk of 
liver cancer among patients with type 2 diabetes (odds ratio 0.38, 95% CI 0.24, 0.59)(82). 
In the Shujuan Ma study, by reviewing studies that had used metformin as a liver-cancer 
risk reducer in diabetic patients, OR was estimated 0.52 (83). In the Hong Hu study, by 
checking the association between metformin and the risk of pancreatic cancer in patients 
with type 2 diabetes RR estimated 0.61 (84). The results of studies on the relationship 
between metformin use and the risk of colorectal, pancreatic and pancreatic cancers, as 
well as current meta-analysis, have a preventive effect. That is, the results of the above 
studies are consistent with the current study result. 
Although previous systematic studies concluded that there is no relationship between 
metformin consumption and the risk of prostate cancer, due to differences in populations, 
statistical analysis, and definitions of high risk, there is a significant heterogeneity (85, 
86). In the Hiroshi Noto meta-analysis in 2011, the odds ratio of metformin consumption 
and prostate cancer was estimated to be 0.89 (95%CI: 0.66-1.19), which is consistent with 
the outcome of the present study (87). In one study, A total of eight studies fulfilled the 
eligibility criteria. We found that diabetic PCa patients who did not use metformin were at 
increased risk of cancer recurrence (RR, 1.20; 95%CI, 1.00-1.44), compared with those 
who used metformin(88). The results of the Davide Soranna study showed that metformin 
and sulfonyl in 37632 type 2 diabetic patients decreased the risk of cancer, which RR: 0.61 
was for all cancers and for prostate and breast cancer RR was 0.87 (26234 prostate - 1068 
breast) (89). The results of studies on the relationship between metformin use and the risk 
of prostate cancer are consistent with the current study. The odds ratio of metformin and 
the risk of prostate cancer estimated in the current study was equal to the last meta-
analysis performed in this ground, and there were no difference in the outcomes, because 
in both studies OR <1, and the OR confidence interval interrupted the number one 
indicating that it was not statistically significant. 
Limitations of study:  
1- Due to the non-uniformity of the conditions of the studies, sample sizes and screening 
method, it is not possible to accurately generalize the exact results of the distinct continents 
and countries. 2- Given that no clinical study was conducted on African countries, we were 
unable to report the statistics from the African continent. 3-The number of explored 
studies was limited. 
Conclusion:  
The odds ratio of metformin use for reducing prostate cancer was 0.89 (95% confidence 
intervalCI: 0.67-1.17), which was not statistically significant. Given the variability in the 
results of various studies and the limited number of studies, more clinical studies are 
needed to provide a definitive opinion on the metformin intake effect or lack thereof on the 
decline of prostate cancer. Metformin consumption was a preventive factor in prostate 
cancer in the continents of Asia, Europe and the United States, although all three were not 
statistically significant. In studying the results derived from several distinct countries, we 
also found that metformin was a preventive factor in prostate cancer in Taiwan, 
Switzerland and Denmark, which was statistically significant, but the results of other 
countries were not statistically significant. In the analysis which was conducted based on 
different treatment durations of the patients, the odds ratio (OR) for the group treated 
under 5 years was less than the group treated for 5 to 10 years. In both groups, metformin 
had a preventive role in prostate cancer, but both were not statistically significant.  
Regarding the age of the patients it can be noted that as the age of the patients increases, 
the odds ratio (OR) also increases. In other words, in the 64-70 age group, metformin has 
a preventive role in prostate cancer and is not statistically significant. But in the 71 to 77 
age group, metformin is a risk factor for prostate cancer, which is still not statistically 
significant. 
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